Your browser doesn't support javascript.
loading
Assessing the utility of common arguments used in expert review of in silico predictions as part of ICH M7 assessments.
Cayley, Alex N; Foster, Robert S; Brigo, Alessandro; Muster, Wolfgang; Musso, Alyssa; Kenyon, Michelle O; Parris, Patricia; White, Angela T; Cohen-Ohana, Mirit; Nudelman, Raphael; Glowienke, Susanne.
Affiliation
  • Cayley AN; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK.
  • Foster RS; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK. Electronic address: robert.foster@lhasalimited.org.
  • Brigo A; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Muster W; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Musso A; Pfizer Global Research and Development, Drug Safety Research and Development, Eastern Point Road, MS 8274/1317, Groton, CT, 06340, USA.
  • Kenyon MO; Pfizer Global Research and Development, Drug Safety Research and Development, Eastern Point Road, MS 8274/1317, Groton, CT, 06340, USA.
  • Parris P; Pfizer Worldwide Research and Development, Drug Safety Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK.
  • White AT; GlaxoSmithKline Pre-Clinical Development, Park Road, Ware, Hertfordshire, SG12 0DP, UK.
  • Cohen-Ohana M; Teva Pharmaceutical Industries Ltd, Dvora HaNevi'a Street 124, Tel Aviv-Yafo, 6944020, Israel.
  • Nudelman R; Teva Pharmaceutical Industries Ltd, Dvora HaNevi'a Street 124, Tel Aviv-Yafo, 6944020, Israel.
  • Glowienke S; Novartis AG, NIBR, Pre-clinical Safety, Fabrikstrasse 16, CH-405, Basel, Switzerland.
Regul Toxicol Pharmacol ; 144: 105490, 2023 Oct.
Article de En | MEDLINE | ID: mdl-37659712
ABSTRACT
Expert review of two predictions, made by complementary (quantitative) structure-activity relationship models, to an overall conclusion is a key component of using in silico tools to assess the mutagenic potential of impurities as part of the ICH M7 guideline. In lieu of a specified protocol, numerous publications have presented best practise guides, often indicating the occurrence of common prediction scenarios and the evidence required to resolve them. A semi-automated expert review tool has been implemented in Lhasa Limited's Nexus platform following collation of these common arguments and assignment to the associated prediction scenarios made by Derek Nexus and Sarah Nexus. Using datasets primarily donated by pharmaceutical companies, an automated analysis of the frequency these prediction scenarios occur, and the likelihood of the associated arguments assigning the correct resolution, could then be conducted. This article highlights that a relatively small number of common arguments may be used to accurately resolve many prediction scenarios to a single conclusion. The use of a standardised method of argumentation and assessment of evidence for a given impurity is proposed to improve the efficiency and consistency of expert review as part of an ICH M7 submission.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies / Risk_factors_studies Langue: En Journal: Regul Toxicol Pharmacol Année: 2023 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies / Risk_factors_studies Langue: En Journal: Regul Toxicol Pharmacol Année: 2023 Type de document: Article Pays d'affiliation: Royaume-Uni
...